Meeting
2018 ASCO Annual Meeting
Off treatment survival (OTS) in patients (pts) with advanced melanoma after anti-PD1 therapy.
Authors
Shelly Ann Christiansen
Georgetown Lombardi Comprehensive Cancer Center, Washington, DC
Shelly Ann Christiansen , David Swoboda , Kellie Gardner , Suthee Rapisuwon , Michael B. Atkins , Geoffrey Thomas Gibney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 36, 2018 (suppl; abstr 9554)
DOI
10.1200/JCO.2018.36.15_suppl.9554
Abstract #
9554
Poster Bd #
381
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Estimating treatment-free survival (TFS) over extended follow-up in patients (pts) with advanced melanoma (MEL) treated with immune-checkpoint inhibitors (ICIs): Five-year follow-up of CheckMate 067.
First Author: Meredith M. Regan
Poster
2020 ASCO Virtual Scientific Program
Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD).
First Author: Lauren Julia Brown
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy and toxicities of immune checkpoint inhibitors (ICIs) in advanced melanoma: A single institution experience.
First Author: Karim Welaya
Poster
2018 ASCO Annual Meeting
Anti-PD1 antibodies in late elderly advanced melanoma patients: A retrospective multicentre study.
First Author: Francesco De Rosa